EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial

Lutz van Heek, Jasmin Weindler, Claudia Gorniak, Helen Kaul, Horst Müller, Jasmin Mettler, Christian Baues, Michael Fuchs, Peter Borchmann, Justin Ferdinandus, Markus Dietlein, Conrad-Amadeus Voltin und 2 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Lutz van Heek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HD17 trial was funded by the German Cancer Aid..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The prognostic relevance of metabolic tumor volume (MTV) having recently been demonstrated in patients with early‐stage favorable and advanced‐stage Hodgkin lymphoma. The current study aimed to assess the potential prognostic value of 18 F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) in early‐stage unfavorable Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD17 trial.

Methods

18 F‐FDG PET/CT images were available for MTV analysis in 154 cases. We used three different threshold methods (SUV 2.5 , SUV 4.0 , and SUV 41% ) to calculate MTV. Receiver‐operating‐characteristic analysis was performed to describe the value of these parameters in predicting an adequate therapy response. Therapy response was evaluated as PET negativity after 2 cycles of eBEACOPP followed by 2 cycles of ABVD.

Results

All three threshold methods analyzed for MTV showed a positive correlation with the PET response after chemotherapy. Areas under the curve (AUC) were 0.70 (95% CI 0.53–0.87) and 0.65 (0.50–0.80) using the fixed thresholds of SUV 4.0 and SUV 2.5 , respectively, for MTV‐ calculation. The calculation of MTV using a relative threshold of SUV 41% showed an AUC of 0.63 (0.47–0.79).

Conclusions

MTV does have predictive value after chemotherapy in early‐stage unfavorable Hodgkin lymphoma, particularly when the fixed threshold of SUV 4.0 is used for MTV calculation.

Trial registration

ClinicalTrials.gov NCT01356680.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHumansPrognosisPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18Tumor BurdenAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinVinblastineBleomycinDacarbazinePositron-Emission TomographyRetrospective Studies

Stichwörter der Autor:innen

FDG PETHodgkin lymphomametabolic tumor volumeresponse prediction

Substanzen

Fluorodeoxyglucose F18DoxorubicinVinblastineBleomycinDacarbazine

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of C…
  • Department of Radiooncology, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany.

Förderung

  • HD17 trial was funded by the German Cancer Aid.

Zitieren

APA

van Heek, L., Weindler, J., Gorniak, C., Kaul, H., Müller, H., Mettler, J., Baues, C., Fuchs, M., Borchmann, P., Ferdinandus, J., Dietlein, M., Voltin, C. A., Kobe, C., & Roth, K. S. (2023). Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial. European Journal of Haematology. https://doi.org/10.1111/ejh.14093

Vancouver

van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, et al. Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial. European Journal of Haematology. 2023. doi:10.1111/ejh.14093

BibTeX
@article{vanHeek2023,
  author = {van Heek, Lutz and Weindler, Jasmin and Gorniak, Claudia and Kaul, Helen and Müller, Horst and Mettler, Jasmin and Baues, Christian and Fuchs, Michael and Borchmann, Peter and Ferdinandus, Justin and Dietlein, Markus and Voltin, Conrad-Amadeus and Kobe, Carsten and Roth, Katrin S},
  title = {Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14093}
}
Kostenlos starten →